Each of the qualities and properties discussed for selective “targeted” chemotherapeutic delivery and additive or synergistic interactions that can be evoked by gemcitabine-(C4-amide)-[anti-EGFR] and epirubicin-(C3-amide)-[anti-HER2/neu] collectively serve to explain how the dual-combination of these two covalent immunochemotherapeutics produced additive levels of anti-neoplastic cytotoxicity against chemotherapeutic-resistant mammary-adenocarcinoma (SKBr-3) when utilized as an ex-vivo model for neoplastic disease (Figures. The gene discussed is ERBB2; the disease is breast adenocarcinoma.